Evaluation of Leg Muscular Activity Using MRI and 11C-acetate PET/MRI. Pilot Study

NCT ID: NCT02969603

Last Updated: 2016-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-30

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study is conceived as a pilot study aimed to determine the efficiency of the newly available Positron Emission Tomography (PET) - Magnetic Resonance Imaging (MRI) hybrid scan technique for muscular activity evaluation, creation of anatomic images of muscle activity and resolution of metabolic activity distribution within exercising skeletal muscle.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

PET/MRI muscular activity 11C-acetate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy volunteers- MRI

MRI scan for morphological assessment of muscle structures and anatomy

Group Type OTHER

Magnetic Resonance Imaging

Intervention Type OTHER

Magnetic Resonance Imaging as reference

Healthy Volunteers- PET/MRI

The volunteers will undergo a combined \[11C\]acetate PET/MRI scan

Group Type OTHER

Magnetic Resonance combined with Positron Emission Tomography

Intervention Type OTHER

Comparison with MRI only, to assess muscular activity, creation of anatomic images of muscle activity and resolution of metabolic activity distribution within exercising skeletal muscle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnetic Resonance Imaging

Magnetic Resonance Imaging as reference

Intervention Type OTHER

Magnetic Resonance combined with Positron Emission Tomography

Comparison with MRI only, to assess muscular activity, creation of anatomic images of muscle activity and resolution of metabolic activity distribution within exercising skeletal muscle

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male volunteer aged in the range 18 to 35 years.
* Acceptance of the research protocol: signature of the informed consent form after oral and written information about the protocol through the patient information document.
* Volunteers that could undergo 1h15 to 1h30 immobilization (MRI exam duration in time).


* Male volunteer aged in the range 18 to 35 years.
* Acceptance of the research protocol: signature of the informed consent form after oral and written information about the protocol through the patient information document.
* Volunteers that could undergo 1.5 to 2.0 hours immobilization (PET/MRI exam duration in time).
* Volunteers should practice regular physical activity, defined as 50 min per day (in a single session), 2 days per week of physical activity as a minimum (no maximum is fixed).

Exclusion Criteria

* Pre-existing neurological or muscular lesions on the legs.
* Co morbidities impeding on the protocol comprehension or fulfilment.
* Illnesses that do not allow to lay down on an examination table.
* Pacemaker holder.
* Metal implants that would preclude MRI imaging
* Claustrophobia: Subjects will be questioned about possible discomfort with being in an enclosed space (e.g., MRI scanner). Those who report such problems will be excluded.


* Medical radiation exposure within the last five years (normal population should not be exposed to medical radiation higher or equal to 1 mSv per year).
* Pre-existing neurological or muscular lesions on the legs.
* Co morbidities impeding on the protocol comprehension or fulfilment.
* Illnesses that do not allow to lay down on an examination table.
* Pacemaker holder.
* Metal implants that would preclude MRI imaging
* Claustrophobia: Subjects will be questioned about possible discomfort with being in an enclosed space (e.g., MRI scanner). Those who report such problems will be excluded.
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Osman Ratib

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Osman Ratib

Dr.

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Osman Ratib, Pr.

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Geneva

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de Medecine Nucléaire et Imagerie moléculaire- HUG

Geneva, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013DR2115

Identifier Type: -

Identifier Source: org_study_id